The Good: Disney Disney’s beloved Marvel movies returned to theaters this year for the first time since the pandemic began. The latest offering—Black Widow, starring Scarlett Johansson—was another smash for the mouse house, hitting a pandemic high in its debut of $80 million. This alone would be a significant achievement as movie theaters continue to find their ground during a delayed blockbuster season. But Black Widow also marks the first true victory for Disney’s hybrid release model, which offers normal theater releases on top of a premium Disney+ release. The at-home model garnered an additional $60 million for Disney. The stock moved confidently to the green as Disney eyes its future hybrid options. The Bad: Virgin Galactic As Virgin Galactic owner Richard Branson took a landmark trip to space, Virgin Galactic’s stock stayed firmly here on earth. The stock fell 17% Shares of Virgin Galactic slipped on Monday after the company filed to sell up to $500 million in common stock. Despite the major milestone achieved by the crew who took Branson to space today, which keeps the company’s goal of opening up commercial space passengers in 2022. The company has nearly 600 reservations on future flights, priced between $200,000 and 250,000 each. Despite the publicity coup seen today, analysts are concerned about the stock sale.Nevertheless, the stock is still up over 80% this year. The Ugly: Biogen Until Friday, Biogen was having a banner year following an approval of what was touted as a revolutionary Alzheimers medicine. The Food and Drug Administration approval garnered a good deal of controversy among over the voracity of the drug. Last week, Biogen shares fell after the head of the Food and Drug Administration called for an investigation into the approval. The drug proposes to slow cognitive decline in people with Alzheimer’s and marks the first new medicine for the disease in nearly twenty years. However, the approval marked a departure from the advice of the agency’s independent panel of outside experts, who declined to endorse the drug. Three members of the panel went as far as to resign in protest following the approval. The science behind the medicine has been met with scrutiny from medical professionals, including some doctors who refuse to prescribe the medicine.